Compare BHP & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHP | NVS |
|---|---|---|
| Founded | 1851 | 1895 |
| Country | Australia | Switzerland |
| Employees | 90000 | 75267 |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 225.5B | 286.5B |
| IPO Year | N/A | N/A |
| Metric | BHP | NVS |
|---|---|---|
| Price | $82.72 | $149.16 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 5 |
| Target Price | $52.50 | ★ $144.00 |
| AVG Volume (30 Days) | ★ 2.4M | 1.3M |
| Earning Date | 02-17-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.41% | 2.16% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.28 | $2.30 |
| Revenue Next Year | N/A | $5.27 |
| P/E Ratio | $37.02 | ★ $23.13 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $45.98 | $112.34 |
| 52 Week High | $93.70 | $170.46 |
| Indicator | BHP | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 45.13 | 49.64 |
| Support Level | $80.98 | $145.30 |
| Resistance Level | $91.45 | $152.55 |
| Average True Range (ATR) | 1.98 | 1.93 |
| MACD | -0.38 | -0.25 |
| Stochastic Oscillator | 14.15 | 59.99 |
BHP is a global diversified miner mainly supplying iron ore and copper. The merger of BHP Limited and Billiton PLC created the present-day BHP Group. The dual-listed structure from the 2001 BHP and Billiton merger was collapsed in 2022. Major assets include Pilbara iron ore and Escondida copper. Onshore US oil and gas assets were sold in 2018, and the remaining Petroleum assets were spun off and merged with Woodside in 2022, with BHP vesting the Woodside shares it received to BHP shareholders. It purchased copper miner Oz Minerals in fiscal 2023 and half of the Vicuna copper joint venture in fiscal 2025. It is entering the potash market through the development of its Jansen project in Canada. However, due to low prices, BHP placed its nickel business on care and maintenance in 2024.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.